Success Metrics

Clinical Success Rate

66.7%

Based on 4 completed trials

Completion Rate

67%(4/6)

Active Trials

3(30%)

Results Posted

75%(3 trials)

Terminated

2(20%)

Phase Distribution

Ph early_phase_1

10%

Ph phase_4

10%

Ph not_applicable

10%

Ph phase_3

10%

Ph phase_2

30%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Early Phase 1First-in-human

1(14.3%)

Phase 2Efficacy & side effects

3(42.9%)

Phase 3Large-scale testing

1(14.3%)

Phase 4Post-market surveillance

1(14.3%)

N/ANon-phased studies

1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(4)

Terminated(2)

Other(1)

Detailed Status

Completed4

Terminated2

Active, not recruiting2

unknown1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (14.3%)

Phase 23 (42.9%)

Phase 31 (14.3%)

Phase 41 (14.3%)

N/A1 (14.3%)

Trials by Status

terminated220%

unknown110%

active_not_recruiting220%

recruiting110%

completed440%

Recent Activity

3 active trials

Showing 5 of 10

active_not_recruiting

CDK and Body Composition Study

NCT03697577

active_not_recruitingphase_2

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

NCT03789240

recruiting

Prospective 4D CTA of BAV Competence

NCT04645862

terminatedphase_2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

NCT06865677

terminatedphase_2

Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

NCT04337827

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT03697577

CDK and Body Composition Study

Active Not Recruiting

NCT03789240Phase 2

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Active Not Recruiting

NCT04645862

Prospective 4D CTA of BAV Competence

Recruiting

NCT06865677Phase 2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Terminated

NCT04337827Phase 2

Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

Terminated

NCT03922828

Lung Nodule Prospective Database

Completed

NCT03764163Early Phase 1

Image and Model Based Analysis of Lung Disease

Completed

NCT02738346Phase 3

SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

Unknown

NCT00500513Not Applicable

Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials

Completed

NCT00108615Phase 4

Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance

Completed

All 10 trials loaded

Drug Details

Intervention Type: DIAGNOSTIC TEST
Total Trials: 10